Advertisement

Picture EBD Group Asia Bio Partnering Forum 2023 Singapore 650x100px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Ireland and UK or involving organisations from these countries.

Total search results: 2749 | Ordered by Date (descending)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Aldena Therapeutics–Medicxi: investment, 202303 Aldena emerges with $30m investment from co-founder Medicxi 2023-03-16
Teitur Trophics–Optimum Strategic Communications: public relations, 202303 service existent by Optimum 2023-03-14
UCB–Cancer Research UK: antibody cancer drugs, 202303– collab clinical development of UCB6114 + UCB4594 2023-03-09
AstraZeneca–Personalis: precision oncology, 202303– collab continuation use of NeXT Personal assay for clinical reserach + drug development 2023-03-07
Antiverse–SEVERAL: investment, 202303 financing round $3m from existing + new investors 2023-03-01
Five Alarm Bio–Acceleris: investment, 202302 seed financing round totalling >£500k incl angel investors with support from KPMG Acceleris 2023-02-27
Five Alarm Bio–Cambridge Angels: investment, 202302 seed financing round totalling >£500k incl investor Cambridge Angels 2023-02-27
Five Alarm Bio–Meltwind: investment, 202302 seed financing round totalling >£500k incl investor Meltwind 2023-02-27
Five Alarm Bio–o2h: investment, 202302 seed financing round totalling >£500k incl investor o2h Ventures 2023-02-27
Five Alarm Bio–SEVERAL: investment, 202302 seed financing round >£500k 2023-02-27
Five Alarm Bio–SyndicateRoom: investment, 202302 seed financing round totalling >£500k incl investor SyndicateRoom 2023-02-27
Five Alarm Bio–Zyme Communications: public relations, 202302 service existent by Zyme 2023-02-27
Lift BioSciences–Consilium: public relations, 202302 service existent by Consilium Strategic Communications 2023-02-16
Lift BioSciences–Resonac: biologics contract manufacturing, 202302– collab developm + manufacturing of N-LIfT for clinical trials by Minaris RM 2023-02-16
Astrea Bioseparations–Biotage: investment, 202302– acquisition $190m in shares + $45 cash milestones of Astrea from Gamma Biosciences (KKR) 2023-02-15
Biotage–KKR: investment, 202302– investment $25m tog with sale of Astrea Bioseparations by Gamma for shares resulting in 17% share in Biotage of Gamma 2023-02-15
Maxion Therapeutics–BGF: investment, 202302 financing round Series A totalling £13m incl co-investor BGF 2023-02-15
Maxion Therapeutics–LifeArc: investment, 202302 financing round Series A totalling £13m incl lead investor LifeArc Ventures 2023-02-15
Maxion Therapeutics–Monograph Capital: investment, 202302 financing round Series A totalling £13m incl co-investor Monograph Capital 2023-02-15
Maxion Therapeutics–SEVERAL: investment, 202302 financing round Series A £13m led by LifeArc Ventures 2023-02-15
Cerevance–SEVERAL: investment, 202302 financing round Series B extension $51m bringing total Series B to $116m 2023-02-13
Cydar–SEVERAL: investment, 202302 financing round Series A £9.3m led by Pembroke VCT + Downing Healthcare Ventures 2023-02-13
HEL Group–Zyme Communications: public relations, 202302 service existent by Zyme 2023-02-08
Evonetix–Cambridge Consultants: investment, 202302 financing round Series B extension totalling £20m incl existing + co-investor Cambridge Consultants 2023-02-07
Evonetix–Civilization Ventures: investment, 202302 financing round Series B extension totalling £20m incl existing + co-investor Civilization Ventures 2023-02-07
Evonetix–DCVC: investment, 202302 financing round Series B extension totalling £20m incl existing + co-investor DCVC 2023-02-07
Evonetix–Foresite Capital: investment, 202302 financing round Series B extension totalling £20m incl existing + lead investor Foresite Capital 2023-02-07
Evonetix–Molten Ventures: investment, 202302 financing round Series B extension totalling £20m incl existing + co-investor Molten Ventures 2023-02-07
Evonetix–Morningside: investment, 202302 financing round Series B extension totalling £20m incl existing + co-investor Morningside 2023-02-07
Evonetix–Providence Investment: investment, 202302 financing round Series B extension totalling £20m incl existing + co-investor Providence 2023-02-07
Evonetix–SEVERAL: investment, 202302 financing round Series B extension £20m bringing total Series B to £43m 2023-02-07
AstraZeneca–Capitainer: sample extraction, 202301– collab research using CapitainerCF self-sampling for clinical research with AZ R&D Gothenbur 2023-01-30
DeuterOncology–Andrew Lloyd Associates: public relations, 202301 service existent by ALA 2023-01-19
Blackford Analysis–Bayer: investment, 202301–202302 acquisition by Bayer 2023-01-18
Vésale Bioscience–Andrew Lloyd Associates: public relations, 202301 service existent by ALA 2023-01-17
Delta Precision–Astrea Bioseparations: investment, 202301 acquisition of Delta Precision Ltd by Astrea 2023-01-09
Proteros–Inflexion: investment, 202301– minority investment by Inflexion with founder + CEO Torsten Neuefeind remaing majority shareholder + CEO 2023-01-09
Amryt Pharma–Chiesi: investment, 202301– acquisition $1.25b upfront cash for all ADSs plus CVRs representing potential $225m consideration ANNOUNCED 2023-01-08
Akamis Bio–ARCH Venture: credit, 202301 convertible note financing totalling $30m incl new + co-lead investor ARCH Venture Partners 2023-01-05
Akamis Bio–Parker Institute: credit, 202301 convertible note financing totalling $30m incl new + co-lead investor Parker Institute 2023-01-05
Akamis Bio–SEVERAL: credit, 202301 convertible note financing $30m co-led by ARCH Venture + Parker Institute + Westalke Village BioPartners 2023-01-05
Akamis Bio–Westlake Village BioPartners: credit, 202301 convertible note financing totalling $30m incl new + co-lead investor Westlake Village BP 2023-01-05
Torreya–Stifel: investment, 202212– acquisition €na of Torreya Partners LLC by Stifel ANNOUNCED 2022-12-22
Inceptor Bio–Ori Biotech: CAGT manufacturing technology, 202212– collab early access to Ori Biotech’s fully automated CGT manufacturing platform 2022-12-15
Ono Pharmaceutical–PrecisionLife: drug target discovery, 202212– collab r+d drug targets + biomarker discovery for CNS drugs 2022-12-14
Storm Therapeutics–Cambridge Innovation Capital: investment, 202212 financing round Series B totalling $30m incl existing + co-lead investor CIC 2022-12-14
Storm Therapeutics–Fast Track Initiative: investment, 202212 financing round Series B totalling $30m incl new + co-lead investor FTI 2022-12-14
Storm Therapeutics–IP Group: investment, 202212 financing round Series B totalling $30m incl existing + co-investor IP Group plc 2022-12-14
Storm Therapeutics–Merck (DE): investment, 202212 financing round Series B totalling $30m incl existing + co-lead investor M Ventures 2022-12-14
Storm Therapeutics–Otsuka: investment, 202212 financing round Series B totalling $30m incl existing + co-lead investor Taiho Ventures LLC 2022-12-14
Storm Therapeutics–Pfizer: investment, 202212 financing round Series B totalling $30m incl existing + co-lead investor Pfizer Ventures 2022-12-14
Storm Therapeutics–Seroba: investment, 202212 financing round Series B totalling $30m incl existing + co-investor Seroba Life Sciences 2022-12-14
Storm Therapeutics–SEVERAL: investment, 202212 financing round Series B $30m led by M Ventures + Pfizer Ventures + Taiho Ventures + CIC 2022-12-14
Storm Therapeutics–Univ Tokyo: investment, 202212 financing round Series B totalling $30m incl new + co-lead investor UTokyo IPC 2022-12-14
BehaVR–Accenture Ventures: investment, 202212 financing round Series B totalling $13m incl co-investor Accenture Ventures 2022-12-13
BehaVR–Chrysalis Ventures: investment, 202212 financing round Series B totalling $13m incl co-investor Chrysalis Ventures 2022-12-13
BehaVR–Confluent Health: investment, 202212 financing round Series B totalling $13m incl co-investor Confluent Health 2022-12-13
BehaVR–Oxford Science Enterprises: investment, 202212 financing round Series B totalling $13m incl co-lead investor Oxford Science Enterprises 2022-12-13
BehaVR–SEVERAL: investment, 202212 financing round Series B $13m led by Optum Ventures + Oxford Science Enterprises 2022-12-13
BehaVR–Thornton Capital: investment, 202212 financing round Series B totalling $13m incl co-investor Thornton Capital 2022-12-13
BehaVR–UnitedHealth: investment, 202212 financing round Series B totalling $13m incl co-lead investor Optum Ventures 2022-12-13
Green Bioactives–Javelin Ventures: investment, 202212 seed financing round totalling £2.6m incl lead investor Eos Advisory LLP 2022-12-13
Green Bioactives–Milltrust International: investment, 202212 seed financing round totalling £2.6m incl co-investor Green Earth Ventures Fund 2022-12-13
Green Bioactives–Regenerate Ventures: investment, 202212 seed financing round totalling £2.6m incl co-investor RV Agtech Fund 2022-12-13
Green Bioactives–Scotland (govt): investment, 202212 seed financing round totalling £2.6m incl co-investor Scottish Enterprise 2022-12-13
Green Bioactives–SEVERAL: investment, 202212 seed financing round £2.6m led by Eos Advisory LLP 2022-12-13
Oxford VR–BehaVR: investment, 202211 merger under BehaVR brand 2022-12-13
Horizon Therapeutics–Amgen: investment, 202212– acquisition recommended cash offer $27.8b for all outstanding shares at $116.5/share 2022-12-12
Cellesce–Danaher: investment, 202212 acquisition of Cellesce by Molecular Devices 2022-12-06
Genezen–Ramarketing: public relations, 202211 service existent Ramarketing is media contact 2022-11-29
Neogene Therapeutics–AstraZeneca: investment, 202211–202301 acquisition $200m upfront + $120 milestones on cash/debt free basis 2022-11-29
Rgenta Therapeutics–AstraZeneca: investment, 202211 financing round Series A totalling $52m incl new + lead investor AZ-CICC Fund 2022-11-29
Rgenta Therapeutics–SEVERAL: investment, 202211 financing round Series A $52m led by AZ-CICC Healthcare Investment Fund 2022-11-29
Touchlight–Gates Foundation: grant, 202211– grant to advance pre-clinical development of doggybone DNA vaccine platform 2022-11-29
V7–Air Street Capital: investment, 202211 financing round Series A totalling $33m incl existing + co-investor Air Street Capital 2022-11-28
V7–Amadeus Capital: investment, 202211 financing round Series A totalling $33m incl existing + co-investor Amadeus Capital Partners 2022-11-28
V7–Partech: investment, 202211 financing round Series A totalling $33m incl existing + co-investor Partech 2022-11-28
V7–PERSON: investment, 202211 financing round Series A totalling $33m incl ML pioneers Francois Chollet + Oriol Vinyals + Jose Valim + Ashish Vaswani 2022-11-28
V7–Radical Ventures: investment, 202211 financing round Series A totalling $33m incl co-lead investor Radical Ventures 2022-11-28
V7–SEVERAL: investment, 202211 financing round Series A $33m co-led by Radical Ventures + Temasek 2022-11-28
V7–Temasek: investment, 202211 financing round Series A totalling $33m incl co-lead investor Temasek 2022-11-28
Turbine–Accel: investment, 202211 financing round Series A totalling €20m incl existing + co-investor Accel 2022-11-22
Turbine–Day One Capital: investment, 202211 financing round Series A totalling €20m incl new + co-investor Day One Capital 2022-11-22
Turbine–Delin Ventures: investment, 202211 financing round Series A totalling €20m incl existing + co-investor Delin Ventures 2022-11-22
Turbine–Mercia: investment, 202211 financing round Series A totalling €20m incl new + co-lead investor Mercia Asset Management 2022-11-22
Turbine–Merck (US): investment, 202211 financing round Series A totalling €20m incl new + co-lead investor MSD GHI Fund 2022-11-22
Turbine–SEVERAL: investment, 202211 financing round Series A €20m co-led by Merck GHI Fund + Mercia Asset Management 2022-11-22
Turbine–XTX Markets: investment, 202211 financing round Series A totalling €20m incl existing + co-investor XTX Ventures 2022-11-22
Accession Therapeutics–SEVERAL: investment, 202211 2nd financing round £16.6m incl iGlobe Partners + Primavera Venture Partners + Birk Venture 2022-11-21
Cradle Bio–Index Ventures: investment, 202211 seed financing round totalling €5.5m incl co-lead investor Index Ventures 2022-11-17
Cradle Bio–Kindred Capital: investment, 202211 seed financing round totalling €5.5m incl co-lead investor Kindred Capital 2022-11-17
Cradle Bio–SEVERAL: investment, 202211 emerges from stealth with €5.5m seed financing round led by Index Ventures + Kindred Capital 2022-11-17
Sarcura–Lansdowne Partners: investment, 202211 seed plus financing round totalling €7m incl existing + co-lead investor Lansdowne Investment Co Cyprus 2022-11-17
Sarcura–SEVERAL: investment, 202211 seed plus financing round €7m co-led by Lansdowne Investment Co Cyprus + IST Cube 2022-11-17
Voyager Therapeutics–Touchlight: dbDNA technology, 202211– license €na to use dbDNA technology in creation of novel capsids 2022-11-15
Sartorius–SEVERAL: credit, 202211– placement of total of €650m Schulschein loans with 3, 5, 7, 10 + 13 years maturity 2022-11-11
NRG Therapeutics–Brandon Capital: investment, 202211 financing round Series A totalling £16m incl new + co-investor Brandon Capital 2022-11-09
NRG Therapeutics–Omega Funds: investment, 202211 financing round Series A totalling £16m incl new + lead investor Omega Funds 2022-11-09
NRG Therapeutics–Parkinson’s UK: investment, 202211 financing round Series A totalling £16m incl founding + co-investor Parkinson’s Virtual Biotech 2022-11-09
NRG Therapeutics–SEVERAL: investment, 202211 financing round Series A £16m led by new investor Omega Funds 2022-11-09
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28  next pagenext page



Advertisement

Picture EBD Group Whitepaper State of Innovation in Europe 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture Berlin Partner Join Cluster HealthCapital Berlin Brandenburg 650x300px

» top